27 December, 2024 | Friday
BioPharma Boardroom
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

IND for phase 2b/3 trial submitted to the FDA   Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approac...

January 24, 2023 | Tuesday | News
Managing Birth Defects for a Lifetime

Birth defects are structural changes present at birth that can affect almost any part of the body. They may affect how the body looks, works or both. The...

January 06, 2023 | Friday | News
Helix and QIAGEN Form Exclusive Global Partnership to Develop and Commercialize Companion Diagnostics for Hereditary Diseases

Partnership to leverage the Helix® Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Ad...

January 06, 2023 | Friday | News

Partner Content

BioPharma BreakThrough's

Editor Picks

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
  View poll results   More polls
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
BioPharma Boardroom

About Us Media Pack Contact Us Privacy Policy

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close